Literature DB >> 20210837

Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease.

L Mechtouff1, E Touzé, P G Steg, E M Ohman, S Goto, A T Hirsch, J Röther, F T Aichner, C Weimar, D L Bhatt, M J Alberts, J-L Mas.   

Abstract

OBJECTIVES: Poor blood pressure (BP) control is common amongst patients with symptomatic atherothrombotic disease. It is unclear whether BP control and management differ across atherothrombotic disease subtypes.
METHODS: We analysed the baseline data of 44,984 patients with documented coronary artery disease (CAD) only (n = 30,414), cerebrovascular disease (CVD) only (n = 11,359) and peripheral arterial disease (PAD) only (n = 3211) from the international REduction of Atherothrombosis for Continued Health Registry and investigated the impact of atherothrombotic disease subtype on BP control and use of antihypertensive drugs.
RESULTS: The proportion of patients with BP controlled (<140/90 mmHg) was higher in CAD (58.1%) than in CVD (44.8%) or PAD (38.9%) patients (P < 0.001). Amongst patients with treated hypertension, CAD patients were more likely to have BP controlled than were CVD patients [odds ratio (OR) = 1.67; 95% confidence interval (CI) = 1.59-1.75] or PAD (OR = 2.30; 95% CI = 2.10-2.52). These differences were smaller in women than in men and decreased with age. Amongst treated patients, CAD patients were more likely to receive > or =3-drug combination therapies than were CVD (OR = 1.73; 95% CI = 1.64-1.83) or PAD (OR = 1.64; 95% CI = 1.49-1.80) patients. Adjustment for age, gender, waist obesity, diabetes, education level and world region did not alter the results.
CONCLUSIONS: Coronary artery disease patients are more likely than CVD or PAD patients to have BP controlled and to receive antihypertensive drugs, particularly combination therapies. Promotion of more effective BP control through combination antihypertensive therapies could improve secondary prevention and therefore prevent complications in CVD and PAD patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20210837     DOI: 10.1111/j.1365-2796.2009.02198.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  3 in total

Review 1.  Genetics of peripheral artery disease.

Authors:  Nicholas J Leeper; Iftikhar J Kullo; John P Cooke
Journal:  Circulation       Date:  2012-06-26       Impact factor: 29.690

2.  Two decades of progress in vascular medicine.

Authors:  Nicholas J Leeper; Jason T Lee; John P Cooke
Journal:  Am J Med       Date:  2011-06-16       Impact factor: 4.965

3.  Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes.

Authors:  Nicholas J Leeper; Anna Bauer-Mehren; Srinivasan V Iyer; Paea Lependu; Cliff Olson; Nigam H Shah
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.